Lasting immune memory against hepatitis B in children after primary immunization with 4 doses of DTPa-HBV-IPV/Hib in the first and 2nd year of life

BMC Infectious Diseases

Research Article

Olivier Van Der Meeren¹  Jeanne-Marie Jacquet¹  Gunasekaran Ramakrishnan²  Britta Gartner³  Michael Steiner⁴  Volker Schuster⁵ 

[1] Clinical Department, GlaxoSmithKline Biologicals, Rixensart, Belgium;Clinical Statistics, GlaxoSmithKline Biologicals, Bangalore, India;Med. Fachbereich Impfstoffe, GlaxoSmithKline Biologicals, Munich, Germany;Medical Practice, Werderstr. 3, 88348, Bad Saulgau, Germany;University Hospital for Children and Adolescents, Leipzig, Germany;

关键词: Booster Vaccination;    Challenge Dose;    Primary Vaccination;    Combination Vaccine;    Immune Memory;   

DOI  :  10.1186/1471-2334-10-9

 received in 2009-07-24, accepted in 2010-01-15,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundFew studies have assessed long term persisting immunity against hepatitis B virus (HBV) in children vaccinated during infancy with combined vaccines containing recombinant HBV surface antigen (HBs). We assessed antibody persistence and immune memory in children 4-5 years of age, previously vaccinated with four doses of combined hexavalent DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™).MethodsImmune memory was assessed in 301 children through administration of a challenge dose of monovalent HBV vaccine.ResultsAt 4-5 years of age, 85.3% of subjects had persisting anti-HBs antibody concentrations ≥ 10 mIU/mL, rising to 98.6% after the HBV challenge dose. All but 12 subjects (95.8%) achieved post-challenge anti-HBs concentrations ≥ 100 mIU/mL. The post-challenge anti-HBs GMC rose by 100-fold compared to pre-challenge concentrations. An anamnestic response to the HBV vaccine challenge was observed in 96.8% of subjects, including 17/21 (81.0%) of children with initially undetectable antibodies (<3.3 mIU/mL). All but 4 of 42 subjects (90.5%) with anti-HBs antibodies <10 mIU/mL prior to the challenge dose, achieved seroprotective levels afterwards. A 4-fold rise in antibody concentration after the challenge dose was observed in 259/264 (98.1%) of initially seropositive subjects. The magnitude of the post-challenge responses was proportional to pre-challenge anti-HBs levels. No serious adverse events were reported during the study.ConclusionThe combined DTPa-HBV-IPV/Hib vaccine induced lasting immune memory against hepatitis B. Long term protection afforded by DTPa-HBV-IPV/Hib is likely to be similar to that observed following priming with monovalent HBV vaccines.Trial registrationhttp://www.clinicaltrials.gov 106789 NCT00411697

【 授权许可】

Unknown   
© Steiner et al; licensee BioMed Central Ltd. 2010. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.